Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for ort…
$166.00+4.16%
报价 2026-11-06
市值
$11.79B
EV
$10.79B
PE (TTM)
24.1x
预期 PE (FY2026)
14.9x
52 周区间距高点 -16.0%
$132.28$197.51
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 11.31 → 12.30（1.1x） | 13.5 |
| FY+32028-12 | 1.1x | 11.31 → 13.41（1.2x） | 12.4 |
毛利率 68% · TTM 收入 $4159M · 基数 EPS 11.31（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ALGNAlign Technology, Inc. | $11.79B | +4.2% | +2.7% | 68.7% | 24.1x | 14.5x | 16.7x | |
| EXELExelixis, Inc. | $17.49B | +1.3% | +11.8% | 96.4% | 14.4x | 11.5x | 20.6x | |
| RVTYRevvity, Inc. | $17.31B | +2.8% | +0.6% | 57.1% | 72.2x | 25.1x | 30.3x | |
| PENPenumbra, Inc. | $12.58B | -0.6% | +15.2% | 67.1% | 74.0x | 59.0x | 71.8x | |
| BMRNBioMarin Pharmaceutical Inc. | $10.85B | -0.2% | +21.6% | 77.1% | 30.1x | 17.2x | 14.9x | |
| ENSGThe Ensign Group, Inc. | $10.56B | -0.7% | +16.7% | 16.6% | 26.4x | 19.5x | 24.1x | |
| QGENQiagen N.V. | $10.39B | -1.0% | +2.8% | 63.6% | 25.8x | 16.0x | 23.2x | |
| BIOBio-Rad Laboratories, Inc. | $10.25B | +3.4% | +0.1% | 51.9% | 9.4x | 9.6x | 27.2x | |
| GMEDGlobus Medical, Inc. | $9.54B | -12.8% | +9.9% | 67.4% | 21.9x | 13.9x | 16.5x | |
| 同行中位数 | – | – | +10.8% | 65.4% | 26.1x | 16.6x | 23.7x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.01B | $1.06B | $1.04B | $1.05B | $995.7M | $1.01B | $979.3M | $995.2M |
| Gross Margin | 68.7% | 65.1% | 70.8% | 65.7% | 64.2% | 69.9% | 69.5% | 70% |
| Operating Margin | 16.7% | 11.7% | 16.6% | 15.2% | 9.7% | 16.1% | 13.4% | 14.5% |
| Net Income | $135M | $108.3M | $112.8M | $135.8M | $56.8M | $124.6M | $93.2M | $103.8M |
| Diluted EPS | 1.9 | 1.52 | 1.57 | 1.89 | 0.78 | 1.72 | 1.27 | 1.39 |
| Operating Cash Flow | $182.9M | $192.8M | $151M | $223.2M | $188.7M | $128.7M | $52.7M | $286.1M |